Hypermutated Gliomas Respond Poorly to Immunotherapy.

Cancer discovery 2020 Jul

filter terms:

all
phenotype
show more »
show less «

Unlike melanomas and colorectal cancers with a high tumor mutation burden, hypermutated gliomas generally do not respond to checkpoint blockade, a study concludes. Hypermutation shortens patient survival, and the results suggest that it occurs because of selective pressure from the chemotherapeutic temozolomide. ©2020 American Association for Cancer Research.